Biostem Technologies Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BSEM Over the counter 2834 https://www.biostemtechnologies.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biostem Technologies Inc

BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products - Mar 23rd, 2023 11:30 am
BSEM: BioStem Expands and Improves - Mar 8th, 2023 11:30 am
BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc. - Mar 7th, 2023 12:30 pm
BioStem Technologies Enters Into a Share Exchange Agreement - Feb 14th, 2023 1:55 pm
BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing - Feb 1st, 2023 12:30 pm
BSEM: Growing Market Size and Opportunity - Jan 31st, 2023 11:15 am
Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions - Jan 24th, 2023 12:30 pm
BioStem Technologies Announces Up-Listing to the OTCQB Venture Market - Dec 16th, 2022 12:30 pm
BioStem Technologies Announces Partnership with Kill Cliff FC - Dec 14th, 2022 12:30 pm
BSEM: Growing Revenues and Expanding Markets - Nov 16th, 2022 12:15 pm
BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results - Nov 15th, 2022 9:05 pm
BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call - Nov 15th, 2022 12:30 pm
BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer - Oct 26th, 2022 11:30 am
BioStem to Present at the Dawson James Securities 2022 Small Cap Growth Conference - Oct 10th, 2022 11:30 am
BSEM: Elevating Skin Grafts to a Higher Level - Sep 20th, 2022 10:15 am
BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts - Sep 13th, 2022 11:30 am
BioStem Technologies Strengthens its Board of Directors and Audit Committee with the Appointment of Accomplished Medtech Financial Leader Brandon Poe - Sep 8th, 2022 11:30 am
BioStem Technologies Reports Second Quarter 2022 Operating and Financial Results - Aug 22nd, 2022 8:01 pm
BioStem Technologies to Host Second Quarter Financial Results and Corporate Update Conference Call on August 22nd - Aug 16th, 2022 11:30 am
BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022 - Jun 17th, 2022 1:25 pm